Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 99-108

  Ko, Eun Ju ^a   Kwon, Young Man ^a   Lee, Jong Seok ^a   Hwang, Hye Suk ^a   Yoo, Si Eun ^a   Lee, Yu Na ^a   Lee, Young Tae ^a   Kim, Min Chul ^a,b   Cho, Min Kyoung ^a   Lee, You Ri ^a   Quan, Fu Shi ^c   Song, Jae Min ^d   Lee, Sujin ^e,f   Moore, Martin L ^e,f   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Sungshin Women's University   (South Korea)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Bronchoalveolar cells; Nanoparticle vaccine; Prophylactic vaccine; RSV

Indexed keywords

CYTOLOGY; DNA; GLYCOPROTEINS; IMMUNE SYSTEM; IMMUNIZATION; MAMMALS; NANOPARTICLES; T-CELLS; VACCINES;

ADAPTIVE IMMUNE RESPONSE; DNA VACCINATION; HUMAN PATHOGENS; IMMUNE CELLS; IMMUNE RESPONSE; RESPIRATORY SYNCYTIAL VIRUS; STRUCTURAL PROTEINS; VIRAL CLEARANCE;

VIRUSES;

CD11B ANTIGEN; DNA; DNA F; FORMALDEHYDE; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN P 15095; NANOPARTICLE; PLASMID DNA; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE NANOPARTICLE; CANCER VACCINE; DNA VACCINE; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNE CELL; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; EOSINOPHILIA; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; INNATE IMMUNE CELL; INNATE IMMUNITY; MOUSE; NONHUMAN; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; VIRAL CLEARANCE; ANIMAL; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INFLAMMATION; METABOLISM; NANOTECHNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD11C; BRONCHOALVEOLAR LAVAGE FLUID; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FEMALE; GLYCOPROTEINS; IMMUNIZATION; IMMUNOGLOBULIN G; INFLAMMATION; MICE; MICE, INBRED BALB C; NANOPARTICLES; NANOTECHNOLOGY; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, DNA;

EID: 84919635691     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.07.013     Document Type: Article

References (47)

1. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82:2040-2055.
2. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
3. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
4. Hancock G.E., Heers K.M., Smith J.D., Scheuer C.A., Ibraghimov A.R., Pryharski K.S. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 2001, 19:4874-4882.
5. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
6. Castilow E.M., Olson M.R., Meyerholz D.K., Varga S.M. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008, 82:2196-2207.
7. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163:693-698.
8. Bont L., Versteegh J., Swelsen W.T., Heijnen C.J., Kavelaars A., Brus F., et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002, 52:363-367.
9. Kang S.M., Song J.M., Quan F.S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res 2009, 143:140-146.
10. Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013, 53:92-107.
11. McGinnes L.W., Gravel K.A., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011, 85:366-377.
12. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010, 84:1110-1123.
13. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000, 81:2519-2523.
14. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999, 73:7099-7107.
15. Martinez X., Li X., Kovarik J., Klein M., Lambert P.H., Siegrist C.A. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur J Immunol 1999, 29:3390-3400.
16. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011, 204:987-995.
17. Stokes K.L., Currier M.G., Sakamoto K., Lee S., Collins P.L., Plemper R.K., et al. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 2013, 87:10070-10082.
18. Shcherbo D., Shemiakina I.I., Ryabova A.V., Luker K.E., Schmidt B.T., Souslova E.A., et al. Near-infrared fluorescent proteins. Nat Methods 2010, 7:827-829.
19. Hotard A.L., Shaikh F.Y., Lee S., Yan D., Teng M.N., Plemper R.K., et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012, 434:129-136.
20. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405:165-175.
21. Quan F.S., Kim Y.C., Yoo D.G., Compans R.W., Prausnitz M.R., Kang S.M. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 2009, 4:e7152.
22. Chirkova T., Boyoglu-Barnum S., Gaston K.A., Malik F.M., Trau S.P., Oomens A.G., et al. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol 2013, 87:13466-13479.
23. Stevens W.W., Kim T.S., Pujanauski L.M., Hao X., Braciale T.J. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods 2007, 327:63-74.
24. Zhang J.Q., Biedermann B., Nitschke L., Crocker P.R. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004, 34:1175-1184.
25. Waris M.E., Tsou C., Erdman D.D., Day D.B., Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 1997, 71:6935-6939.
26. Lee S., Stokes K.L., Currier M.G., Sakamoto K., Lukacs N.W., Celis E., et al. Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol 2012, 86:13016-13024.
27. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
28. Puthothu B., Forster J., Heinzmann A., Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers 2006, 22:303-308.
29. Klein Klouwenberg P., Tan L., Werkman W., van Bleek G.M., Coenjaerts F. The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus. Crit Rev Immunol 2009, 29:531-550.
30. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
31. Haynes L.M., Jones L.P., Barskey A., Anderson L.J., Tripp R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 2003, 77:9831-9844.
32. Varga S.M., Wang X., Welsh R.M., Braciale T.J. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001, 15:637-646.
33. Graham B.S., Henderson G.S., Tang Y.W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993, 151:2032-2040.
34. Blanco J.C., Boukhvalova M.S., Pletneva L.M., Shirey K.A., Vogel S.N. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 2014, 14:1495-1500.
35. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859-865.
36. Boelen A., Andeweg A., Kwakkel J., Lokhorst W., Bestebroer T., Dormans J., et al. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 2000, 19:982-991.
37. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70:2852-2860.
38. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986, 57:721-728.
39. Kamphuis T., Meijerhof T., Stegmann T., Lederhofer J., Wilschut J., de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One 2012, 7:e36812.
40. Johnson T.R., Teng M.N., Collins P.L., Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 2004, 78:6024-6032.
41. Openshaw P.J., Culley F.J., Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001, 20(Suppl. 1):S27-S31.
42. McAleer J.P., Zammit D.J., Lefrancois L., Rossi R.J., Vella A.T. The lipopolysaccharide adjuvant effect on T cells relies on nonoverlapping contributions from the MyD88 pathway and CD11c+ cells. J Immunol 2007, 179:6524-6535.
43. Gelfand E.W. Development of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implications. Curr Opin Immunol 2012, 24:713-719.
44. Villenave R., Shields M.D., Power U.F. Respiratory syncytial virus interaction with human airway epithelium. Trends Microbiol 2013, 21:238-244.
45. Ruotsalainen M., Hyvarinen M.K., Piippo-Savolainen E., Korppi M. Adolescent asthma after rhinovirus and respiratory syncytial virus bronchiolitis. Pediatr Pulmonol 2013, 48:633-639.
46. Connors M., Kulkarni A.B., Firestone C.Y., Holmes K.L., Morse H.C., Sotnikov A.V., et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 1992, 66:7444-7451.
47. Olson M.R., Hartwig S.M., Varga S.M. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 2008, 181:7958-7968.